1. Drug-induced Sarcoid Uveitis with Biologics
- Author
-
Deshka Doycheva, Manfred Zierhut, Edoardo Baglivo, Alan G. Palestine, Ehud Zamir, Ivan R. Schwab, Albert O. Edwards, Elisabetta Miserocchi, Bianka Sobolewska, and Michal Kramer
- Subjects
Drug ,medicine.medical_specialty ,Sarcoidosis ,media_common.quotation_subject ,New onset ,Abatacept ,Uveitis ,Biological Factors ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Immunology and Allergy ,Retrospective Studies ,media_common ,Inflammation ,030203 arthritis & rheumatology ,Biological Products ,business.industry ,Adalimumab ,medicine.disease ,Dermatology ,Infliximab ,humanities ,Biologic Agents ,body regions ,Ophthalmology ,Antirheumatic Agents ,030221 ophthalmology & optometry ,Anti-TNF therapy ,business ,Sarcoid uveitis - Abstract
to evaluate new onset uveitis or reactivated uveitis by biologic agents and characterize their features.This is a multicenter, retrospective case series. Patients under biologic therapy were included if they developed uveitis for the first time or experienced intraocular inflammation which was different in location or laterality to previous inflammation.Sixteen patients were identified. The underlying disorders included ankylosing spondylitis, juvenile idiopathic arthritis, rheumatoid arthritis, and Behçet's Disease. The biologic agents associated with a first episode of uveitis (n = 11) or with a new recurrence of uveitis (n = 5) were etanercept, adalimumab, abatacept, infliximab, and golimumab. Sarcoidosis based on bihilar lymphadenopathy, other computer tomography-findings, or biopsy was diagnosed in five patients under therapy with etanercep, adalimumab, and abatacept. Additionally, seven patients developed clinical changes in their uveitis pattern, suggesting sarcoid uveitis.Biologic treatment-induced uveitis often presents as granulomatous disease.
- Published
- 2021